Market Insights Health Medical Technology

In Vitro Diagnostics - EU-27

EU-27

Revenue in the In Vitro Diagnostics market in European Union (EU27) is projected to reach US$16.39bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 2.51%, resulting in a market volume of US$18.55bn by 2029.
In global comparison, most revenue will be generated in the United States (US$30,100.00m in 2024).

Key regions: China, France, Japan, Netherlands, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The In Vitro Diagnostics market in EU-27 is experiencing steady growth due to several factors.

Customer preferences: Customers in the EU-27 region are increasingly seeking personalized healthcare solutions, leading to a growing demand for In Vitro Diagnostics (IVD) products. The ability of IVD tests to provide accurate and timely diagnostic information is highly valued by patients and healthcare professionals alike. Additionally, the rising prevalence of chronic diseases, such as diabetes and cardiovascular diseases, has further fueled the demand for IVD products in the region.

Trends in the market: One of the key trends in the IVD market in EU-27 is the increasing adoption of point-of-care testing (POCT) devices. These devices allow for rapid and convenient testing at the patient's bedside or in a non-laboratory setting, providing immediate results and enabling faster decision-making by healthcare professionals. The convenience and efficiency offered by POCT devices have made them popular in various healthcare settings, including hospitals, clinics, and home care. Another trend in the market is the growing demand for molecular diagnostics. Molecular diagnostics involve the detection and analysis of genetic material to diagnose diseases and guide treatment decisions. The advancements in technology and the decreasing costs of genetic sequencing have made molecular diagnostics more accessible and affordable. This has led to an increased adoption of molecular diagnostic tests in the EU-27 region, particularly for infectious diseases, cancer, and genetic disorders.

Local special circumstances: The EU-27 region has a well-established healthcare infrastructure and a strong focus on healthcare quality and patient safety. This has created a favorable environment for the growth of the IVD market, as healthcare providers prioritize the use of reliable and accurate diagnostic tests. Additionally, the region has a high level of healthcare expenditure, which allows for greater investment in advanced diagnostic technologies.

Underlying macroeconomic factors: The IVD market in the EU-27 region is influenced by several macroeconomic factors. The aging population in many European countries has led to an increased demand for healthcare services, including diagnostic tests. Furthermore, the implementation of healthcare reforms and policies aimed at improving access to healthcare services has also contributed to the growth of the IVD market. In conclusion, the In Vitro Diagnostics market in EU-27 is experiencing steady growth due to customer preferences for personalized healthcare solutions, the increasing adoption of point-of-care testing devices, and the growing demand for molecular diagnostics. The region's well-established healthcare infrastructure, focus on healthcare quality, and high healthcare expenditure have also contributed to the market's development. The aging population and healthcare reforms are underlying macroeconomic factors that have further fueled the growth of the IVD market in the EU-27 region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.